Search

Your search keyword '"Müller, Martin C."' showing total 592 results
Start Over Author "Müller, Martin C."
592 results on '"Müller, Martin C."'

1. Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study

Author

White, Helen E., Salmon, Matthew, Albano, Francesco, Andersen, Christina Søs Auður, Balabanov, Stefan, Balatzenko, Gueorgui, Barbany, Gisela, Cayuela, Jean-Michel, Cerveira, Nuno, Cochaux, Pascale, Colomer, Dolors, Coriu, Daniel, Diamond, Joana, Dietz, Christian, Dulucq, Stéphanie, Engvall, Marie, Franke, Georg N., Gineikiene-Valentine, Egle, Gniot, Michal, Gómez-Casares, María Teresa, Gottardi, Enrico, Hayden, Chloe, Hayette, Sandrine, Hedblom, Andreas, Ilea, Anca, Izzo, Barbara, Jiménez-Velasco, Antonio, Jurcek, Tomas, Kairisto, Veli, Langabeer, Stephen E., Lion, Thomas, Meggyesi, Nora, Mešanović, Semir, Mihok, Luboslav, Mitterbauer-Hohendanner, Gerlinde, Moeckel, Sylvia, Naumann, Nicole, Nibourel, Olivier, Oppliger Leibundgut, Elisabeth, Panayiotidis, Panayiotis, Podgornik, Helena, Pott, Christiane, Rapado, Inmaculada, Rose, Susan J., Schäfer, Vivien, Touloumenidou, Tasoula, Veigaard, Christopher, Venniker-Punt, Bianca, Venturi, Claudia, Vigneri, Paolo, Vorkinn, Ingvild, Wilkinson, Elizabeth, Zadro, Renata, Zawada, Magdalena, Zizkova, Hana, Müller, Martin C., Saussele, Susanne, Ernst, Thomas, Machova Polakova, Katerina, Hochhaus, Andreas, and Cross, Nicholas C. P.

Published
2022
Full Text
View/download PDF

2. POSTER: CML-310 Early Cytogenetic or Molecular Landmark Response to Ponatinib Treatment Predicts Outcomes in Heavily Pretreated Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in PACE: 5-Year Data

Author

Müller, Martin C., primary, Cortes, Jorge, additional, Chuah, Charles, additional, DeAngelo, Daniel J., additional, Deininger, Michael, additional, Guilhot, François, additional, Hughes, Timothy, additional, Nicolini, Franck E., additional, Pinilla-Ibarz, Javier, additional, Rea, Delphine, additional, Rosti, Gianantonio, additional, Shah, Neil P., additional, Talpaz, Moshe, additional, Lu, Vickie, additional, Padukkavidana, Thihan, additional, and Kantarjian, Hagop M., additional

Published
2023
Full Text
View/download PDF

3. CML-310 Early Cytogenetic or Molecular Landmark Response to Ponatinib Treatment Predicts Outcomes in Heavily Pretreated Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in PACE: 5-Year Data

Author

Müller, Martin C., primary, Cortes, Jorge, additional, Chuah, Charles, additional, DeAngelo, Daniel J., additional, Deininger, Michael, additional, Guilhot, François, additional, Hughes, Timothy, additional, Nicolini, Franck E., additional, Pinilla-Ibarz, Javier, additional, Rea, Delphine, additional, Rosti, Gianantonio, additional, Shah, Neil P., additional, Talpaz, Moshe, additional, Lu, Vickie, additional, Padukkavidana, Thihan, additional, and Kantarjian, Hagop M., additional

Published
2023
Full Text
View/download PDF

4. P670: EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE: 5-YEAR DATA

Author

Müller, Martin C., primary, Cortes, Jorge, additional, Chuah, Charles, additional, Deangelo, Daniel, additional, Deininger, Michael, additional, Guilhot, François, additional, Hughes, Timothy, additional, Emmanuel Nicolini, Franck, additional, Pinilla-Ibarz, Javier, additional, Rea, Delphine, additional, Rosti, Gianantonio, additional, Shah, Neil P., additional, Talpaz, Moshe, additional, Lu, Vickie, additional, Padukkavidana, Thihan, additional, and Kantarjian, Hagop, additional

Published
2023
Full Text
View/download PDF

5. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease

Author

Branford, Susan, Wang, Paul, Yeung, David T., Thomson, Daniel, Purins, Adrian, Wadham, Carol, Shahrin, Nur Hezrin, Marum, Justine E., Nataren, Nathalie, Parker, Wendy T., Geoghegan, Joel, Feng, Jinghua, Shanmuganathan, Naranie, Mueller, Martin C., Dietz, Christian, Stangl, Doris, Donaldson, Zoe, Altamura, Haley, Georgievski, Jasmina, Braley, Jodi, Brown, Anna, Hahn, Christopher, Walker, Ieuan, Kim, Soo-Hyun, Choi, Soo-Young, Park, Sa-Hee, Kim, Dong-Wook, White, Deborah L., Yong, Agnes S.M., Ross, David M., Scott, Hamish S., Schreiber, Andreas W., and Hughes, Timothy P.

Published
2018
Full Text
View/download PDF

6. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Author

Cortes, Jorge E., Kim, Dong-Wook, Pinilla-Ibarz, Javier, le Coutre, Philipp D., Paquette, Ronald, Chuah, Charles, Nicolini, Franck E., Apperley, Jane F., Khoury, H. Jean, Talpaz, Moshe, DeAngelo, Daniel J., Abruzzese, Elisabetta, Rea, Delphine, Baccarani, Michele, Müller, Martin C., Gambacorti-Passerini, Carlo, Lustgarten, Stephanie, Rivera, Victor M., Haluska, Frank G., Guilhot, François, Deininger, Michael W., Hochhaus, Andreas, Hughes, Timothy P., Shah, Neil P., and Kantarjian, Hagop M.

Published
2018
Full Text
View/download PDF

8. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia

Author

Hurtz, Christian, Hatzi, Katerina, Cerchietti, Leandro, Braig, Melanie, Park, Eugene, Kim, Yong-mi, Herzog, Sebastian, Ramezani-Rad, Parham, Jumaa, Hassan, Müller, Martin C, Hofmann, Wolf-Karsten, Hochhaus, Andreas, Ye, B Hilda, Agarwal, Anupriya, Druker, Brian J, Shah, Neil P, Melnick, Ari M, and Müschen, Markus

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Hematology, Stem Cell Research - Nonembryonic - Non-Human, Stem Cell Research - Nonembryonic - Human, Cancer, Rare Diseases, Stem Cell Research, Development of treatments and therapeutic interventions, 2.1 Biological and endogenous factors, 5.1 Pharmaceuticals, Aetiology, Animals, Antigens, CD34, Benzamides, Cell Survival, DNA-Binding Proteins, Disease Models, Animal, Forkhead Transcription Factors, Hematopoietic Stem Cells, Humans, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mice, Mice, Inbred NOD, Mice, Knockout, Mice, SCID, Neoplasm Transplantation, Neoplastic Stem Cells, Piperazines, Protein Kinase Inhibitors, Protein-Tyrosine Kinases, Proto-Oncogene Proteins c-bcl-6, Pyrimidines, Tumor Cells, Cultured, Tumor Suppressor Protein p53, Medical and Health Sciences, Immunology, Biomedical and clinical sciences, Health sciences
Abstract

Chronic myeloid leukemia (CML) is induced by the oncogenic BCR-ABL1 tyrosine kinase and can be effectively treated for many years with tyrosine kinase inhibitors (TKIs). However, unless CML patients receive life-long TKI treatment, leukemia will eventually recur; this is attributed to the failure of TKI treatment to eradicate leukemia-initiating cells (LICs). Recent work demonstrated that FoxO factors are critical for maintenance of CML-initiating cells; however, the mechanism of FoxO-dependent leukemia initiation remained elusive. Here, we identified the BCL6 protooncogene as a critical effector downstream of FoxO in self-renewal signaling of CML-initiating cells. BCL6 represses Arf and p53 in CML cells and is required for colony formation and initiation of leukemia. Importantly, peptide inhibition of BCL6 in human CML cells compromises colony formation and leukemia initiation in transplant recipients and selectively eradicates CD34(+) CD38(-) LICs in patient-derived CML samples. These findings suggest that pharmacological inhibition of BCL6 may represent a novel strategy to eradicate LICs in CML. Clinical validation of this concept could limit the duration of TKI treatment in CML patients, which is currently life-long, and substantially decrease the risk of blast crisis transformation.

Published
2011

10. Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV

Author

Saussele, Susanne, Hehlmann, Rüdiger, Fabarius, Alice, Jeromin, Sabine, Proetel, Ulrike, Rinaldetti, Sebastien, Kohlbrenner, Katharina, Einsele, Hermann, Falge, Christiane, Kanz, Lothar, Neubauer, Andreas, Kneba, Michael, Stegelmann, Frank, Pfreundschuh, Michael, Waller, Cornelius F., Oppliger Leibundgut, Elisabeth, Heim, Dominik, Krause, Stefan W., Hofmann, Wolf-Karsten, Hasford, Joerg, Pfirrmann, Markus, Müller, Martin C., Hochhaus, Andreas, and Lauseker, Michael

Published
2018
Full Text
View/download PDF

11. Supplementary Figure 4 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib

Author

Vigneri, Paolo, primary, Stagno, Fabio, primary, Stella, Stefania, primary, Cupri, Alessandra, primary, Forte, Stefano, primary, Massimino, Michele, primary, Antolino, Agostino, primary, Siragusa, Sergio, primary, Mannina, Donato, primary, Impera, Stefana Stella, primary, Musolino, Caterina, primary, Malato, Alessandra, primary, Mineo, Giuseppe, primary, Tomaselli, Carmela, primary, Murgano, Pamela, primary, Musso, Maurizio, primary, Morabito, Fortunato, primary, Molica, Stefano, primary, Martino, Bruno, primary, Manzella, Livia, primary, Müller, Martin C., primary, Hochhaus, Andreas, primary, and Raimondo, Francesco Di, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Table 2 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib

Author

Vigneri, Paolo, primary, Stagno, Fabio, primary, Stella, Stefania, primary, Cupri, Alessandra, primary, Forte, Stefano, primary, Massimino, Michele, primary, Antolino, Agostino, primary, Siragusa, Sergio, primary, Mannina, Donato, primary, Impera, Stefana Stella, primary, Musolino, Caterina, primary, Malato, Alessandra, primary, Mineo, Giuseppe, primary, Tomaselli, Carmela, primary, Murgano, Pamela, primary, Musso, Maurizio, primary, Morabito, Fortunato, primary, Molica, Stefano, primary, Martino, Bruno, primary, Manzella, Livia, primary, Müller, Martin C., primary, Hochhaus, Andreas, primary, and Raimondo, Francesco Di, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 2 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib

Author

Vigneri, Paolo, primary, Stagno, Fabio, primary, Stella, Stefania, primary, Cupri, Alessandra, primary, Forte, Stefano, primary, Massimino, Michele, primary, Antolino, Agostino, primary, Siragusa, Sergio, primary, Mannina, Donato, primary, Impera, Stefana Stella, primary, Musolino, Caterina, primary, Malato, Alessandra, primary, Mineo, Giuseppe, primary, Tomaselli, Carmela, primary, Murgano, Pamela, primary, Musso, Maurizio, primary, Morabito, Fortunato, primary, Molica, Stefano, primary, Martino, Bruno, primary, Manzella, Livia, primary, Müller, Martin C., primary, Hochhaus, Andreas, primary, and Raimondo, Francesco Di, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 5 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib

Author

Vigneri, Paolo, primary, Stagno, Fabio, primary, Stella, Stefania, primary, Cupri, Alessandra, primary, Forte, Stefano, primary, Massimino, Michele, primary, Antolino, Agostino, primary, Siragusa, Sergio, primary, Mannina, Donato, primary, Impera, Stefana Stella, primary, Musolino, Caterina, primary, Malato, Alessandra, primary, Mineo, Giuseppe, primary, Tomaselli, Carmela, primary, Murgano, Pamela, primary, Musso, Maurizio, primary, Morabito, Fortunato, primary, Molica, Stefano, primary, Martino, Bruno, primary, Manzella, Livia, primary, Müller, Martin C., primary, Hochhaus, Andreas, primary, and Raimondo, Francesco Di, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 1 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib

Author

Vigneri, Paolo, primary, Stagno, Fabio, primary, Stella, Stefania, primary, Cupri, Alessandra, primary, Forte, Stefano, primary, Massimino, Michele, primary, Antolino, Agostino, primary, Siragusa, Sergio, primary, Mannina, Donato, primary, Impera, Stefana Stella, primary, Musolino, Caterina, primary, Malato, Alessandra, primary, Mineo, Giuseppe, primary, Tomaselli, Carmela, primary, Murgano, Pamela, primary, Musso, Maurizio, primary, Morabito, Fortunato, primary, Molica, Stefano, primary, Martino, Bruno, primary, Manzella, Livia, primary, Müller, Martin C., primary, Hochhaus, Andreas, primary, and Raimondo, Francesco Di, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 3 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib

Author

Vigneri, Paolo, primary, Stagno, Fabio, primary, Stella, Stefania, primary, Cupri, Alessandra, primary, Forte, Stefano, primary, Massimino, Michele, primary, Antolino, Agostino, primary, Siragusa, Sergio, primary, Mannina, Donato, primary, Impera, Stefana Stella, primary, Musolino, Caterina, primary, Malato, Alessandra, primary, Mineo, Giuseppe, primary, Tomaselli, Carmela, primary, Murgano, Pamela, primary, Musso, Maurizio, primary, Morabito, Fortunato, primary, Molica, Stefano, primary, Martino, Bruno, primary, Manzella, Livia, primary, Müller, Martin C., primary, Hochhaus, Andreas, primary, and Raimondo, Francesco Di, primary

Published
2023
Full Text
View/download PDF

17. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Author

Deininger, Michael W., Hodgson, J. Graeme, Shah, Neil P., Cortes, Jorge E., Kim, Dong-Wook, Nicolini, Franck E., Talpaz, Moshe, Baccarani, Michele, Müller, Martin C., Li, Jin, Parker, Wendy T., Lustgarten, Stephanie, Clackson, Tim, Haluska, Frank G., Guilhot, Francois, Kantarjian, Hagop M., Soverini, Simona, Hochhaus, Andreas, Hughes, Timothy P., Rivera, Victor M., and Branford, Susan

Published
2016
Full Text
View/download PDF

18. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV

Author

Saußele, Susanne, Krauß, Marie-Paloma, Hehlmann, Rüdiger, Lauseker, Michael, Proetel, Ulrike, Kalmanti, Lida, Hanfstein, Benjamin, Fabarius, Alice, Kraemer, Doris, Berdel, Wolfgang E., Bentz, Martin, Staib, Peter, de Wit, Maike, Wernli, Martin, Zettl, Florian, Hebart, Holger F., Hahn, Markus, Heymanns, Jochen, Schmidt-Wolf, Ingo, Schmitz, Norbert, Eckart, Michael J., Gassmann, Winfried, Bartholomäus, Andrea, Pezzutto, Antonio, Leibundgut, Elisabeth Oppliger, Heim, Dominik, Krause, Stefan W., Burchert, Andreas, Hofmann, Wolf-Karsten, Hasford, Joerg, Hochhaus, Andreas, Pfirrmann, Markus, and Müller, Martin C.

Published
2015
Full Text
View/download PDF

20. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML

Author

Fabarius, Alice, Kalmanti, Lida, Dietz, Christian T., Lauseker, Michael, Rinaldetti, Sébastien, Haferlach, Claudia, Göhring, Gudrun, Schlegelberger, Brigitte, Jotterand, Martine, Hanfstein, Benjamin, Seifarth, Wolfgang, Hänel, Mathias, Köhne, Claus-Henning, Lindemann, Hans W., Berdel, Wolfgang E., Staib, Peter, Müller, Martin C., Proetel, Ulrike, Balleisen, Leopold, Goebeler, Maria-Elisabeth, Dengler, Jolanta, Falge, Christiane, Kanz, Lothar, Burchert, Andreas, Kneba, Michael, Stegelmann, Frank, Pfreundschuh, Michael, Waller, Cornelius F., Spiekermann, Karsten, Brümmendorf, Tim H., Edinger, Matthias, Hofmann, Wolf-Karsten, Pfirrmann, Markus, Hasford, Joerg, Krause, Stefan, Hochhaus, Andreas, Saußele, Susanne, Hehlmann, Rüdiger, and for the SAKK and the German CML Study Group

Published
2015
Full Text
View/download PDF

22. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

Author

Baccarani, Michele, Deininger, Michael W., Rosti, Gianantonio, Hochhaus, Andreas, Soverini, Simona, Apperley, Jane F., Cervantes, Francisco, Clark, Richard E., Cortes, Jorge E., Guilhot, François, Hjorth-Hansen, Henrik, Hughes, Timothy P., Kantarjian, Hagop M., Kim, Dong-Wook, Larson, Richard A., Lipton, Jeffrey H., Mahon, François-Xavier, Martinelli, Giovanni, Mayer, Jiri, Müller, Martin C., Niederwieser, Dietger, Pane, Fabrizio, Radich, Jerald P., Rousselot, Philippe, Saglio, Giuseppe, Saußele, Susanne, Schiffer, Charles, Silver, Richard, Simonsson, Bengt, Steegmann, Juan-Luis, Goldman, John M., and Hehlmann, Rüdiger

Published
2013
Full Text
View/download PDF

32. Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV

Author

Proetel, Ulrike, Pletsch, Nadine, Lauseker, Michael, Müller, Martin C., Hanfstein, Benjamin, Krause, Stefan W., Kalmanti, Lida, Schreiber, Annette, Heim, Dominik, Baerlocher, Gabriela M., Hofmann, Wolf-Karsten, Lange, Elisabeth, Einsele, Hermann, Wernli, Martin, Kremers, Stephan, Schlag, Rudolf, Müller, Lothar, Hänel, Mathias, Link, Hartmut, Hertenstein, Bernd, Pfirrmann, Markus, Hochhaus, Andreas, Hasford, Joerg, Hehlmann, Rüdiger, Saußele, Susanne, and for the German Chronic Myeloid Leukemia Study Group, and the Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK).

Published
2014
Full Text
View/download PDF

34. Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV

Author

Kalmanti, Lida, Saussele, Susanne, Lauseker, Michael, Proetel, Ulrike, Müller, Martin C., Hanfstein, Benjamin, Schreiber, Annette, Fabarius, Alice, Pfirrmann, Markus, Schnittger, Susanne, Dengler, Jolanta, Falge, Christiane, Kanz, Lothar, Neubauer, Andreas, Stegelmann, Frank, Pfreundschuh, Michael, Waller, Cornelius F., Spiekermann, Karsten, Krause, Stefan W., Heim, Dominik, Nerl, Christoph, Hossfeld, Dieter K., Kolb, Hans-Jochem, Hochhaus, Andreas, Hasford, Joerg, Hehlmann, Rüdiger, German Chronic Myeloid Leukemia Study Group, and Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK)

Published
2014
Full Text
View/download PDF

36. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

Author

White, Helen E., Matejtschuk, Paul, Rigsby, Peter, Gabert, Jean, Lin, Feng, Lynn Wang, Y., Branford, Susan, Müller, Martin C., Beaufils, Nathalie, Beillard, Emmanuel, Colomer, Dolors, Dvorakova, Dana, Ehrencrona, Hans, Goh, Hyun-Gyung, El Housni, Hakim, Jones, Dan, Kairisto, Veli, Kamel-Reid, Suzanne, Kim, Dong-Wook, Langabeer, Stephen, Ma, Edmond S.K., Press, Richard D., Romeo, Giuliana, Wang, Lihui, Zoi, Katerina, Hughes, Timothy, Saglio, Giuseppe, Hochhaus, Andreas, Goldman, John M., Metcalfe, Paul, and Cross, Nicholas C.P.

Published
2010
Full Text
View/download PDF

37. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

Author

Hughes, Timothy P., Hochhaus, Andreas, Branford, Susan, Müller, Martin C., Kaeda, Jaspal S., Foroni, Letizia, Druker, Brian J., Guilhot, François, Larson, Richard A., O'Brien, Stephen G., Rudoltz, Marc S., Mone, Manisha, Wehrle, Elisabeth, Modur, Vijay, Goldman, John M., and Radich, Jerald P.

Published
2010
Full Text
View/download PDF

38. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV

Author

Saussele, Susanne, Lauseker, Michael, Gratwohl, Alois, Beelen, Dietrich W., Bunjes, Donald, Schwerdtfeger, Rainer, Kolb, Hans-Jochem, Ho, Anthony D., Falge, Christiane, Holler, Ernst, Schlimok, Günter, Zander, Axel R., Arnold, Renate, Kanz, Lothar, Dengler, Robert, Haferlach, Claudia, Schlegelberger, Brigitte, Pfirrmann, Markus, Müller, Martin C., Schnittger, Susanne, Leitner, Armin, Pletsch, Nadine, Hochhaus, Andreas, Hasford, Joerg, Hehlmann, Rüdiger, and for the German CML Study Group

Published
2010
Full Text
View/download PDF

39. Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation

Author

Nicolini, Franck E., Mauro, Michael J., Martinelli, Giovanni, Kim, Dong-Wook, Soverini, Simona, Müller, Martin C., Hochhaus, Andreas, Cortes, Jorge, Chuah, Charles, Dufva, Inge H., Apperley, Jane F., Yagasaki, Fumiharu, Pearson, Jay D., Peter, Senaka, Sanz Rodriguez, Cesar, Preudhomme, Claude, Giles, Francis, Goldman, John M., and Zhou, Wei

Published
2009
Full Text
View/download PDF

44. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

Author

Branford, Susan, Fletcher, Linda, Cross, Nicholas C.P., Müller, Martin C., Hochhaus, Andreas, Kim, Dong-Wook, Radich, Jerald P., Saglio, Giuseppe, Pane, Fabrizio, Kamel-Reid, Suzanne, Wang, Y. Lynn, Press, Richard D., Lynch, Kevin, Rudzki, Zbigniew, Goldman, John M., and Hughes, Timothy

Published
2008
Full Text
View/download PDF

45. SOCS-2 gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatment.

Author

Egeli, Damla Buket, Hanfstein, Benjamin, Lauseker, Michael, Pfirrmann, Markus, Saussele, Susanne, Baerlocher, Gabriela M., and Müller, Martin C.

Subjects
CHRONIC myeloid leukemia, GENE expression, IMATINIB, PROGRESSION-free survival
Abstract

SOCS-2 gene expression at diagnosis has been suggested as a predictor of clinical outcome in chronic myeloid leukemia (CML). In this study SOCS-2 and GUS expression levels were determined by real-time PCR in pretherapeutic samples at diagnosis. First, three patient groups were compared after assessment at 48 months: optimal molecular responders (n = 35), patients with resistance to imatinib (n = 28), and blast crisis patients (n = 27). A significant difference in SOCS-2 gene expression at diagnosis was observed comparing blast crisis vs. resistant patients (p = 0.042) and optimal responders (p = 0.010). Second, a validation sample of consecutively randomized patients (n = 123) was investigated. No discriminative SOCS-2 gene expression cutoff could be derived to predict molecular or cytogenetic response, progression-free or overall survival. Although SOCS-2 gene was differentially expressed at the time of diagnosis in blast crisis patients when compared to other groups, a prognostic impact in consecutively randomized patients was not observed. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results